Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Zealand Pharma

DB:22Z
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
22Z
DB
DKK8B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Zealand Pharma A/S, a biotechnology company, engages in the discovery and development of peptide based medicines in Denmark. The last earnings update was 28 days ago. More info.


Add to Portfolio Compare Print
  • Zealand Pharma has significant price volatility in the past 3 months.
22Z Share Price and Events
7 Day Returns
2.8%
DB:22Z
5.2%
DE Biotechs
4.3%
DE Market
1 Year Returns
79.6%
DB:22Z
-7.4%
DE Biotechs
-14.2%
DE Market
22Z Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Zealand Pharma (22Z) 2.8% -6.4% -1.1% 79.6% 85.3% 108.4%
DE Biotechs 5.2% -3.3% -20.3% -7.4% 19.5% -9.4%
DE Market 4.3% -9% -21.6% -14.2% -19.6% -25.6%
1 Year Return vs Industry and Market
  • 22Z outperformed the Biotechs industry which returned -7.4% over the past year.
  • 22Z outperformed the Market in Germany which returned -14.2% over the past year.
Price Volatility
22Z
Industry
5yr Volatility vs Market

Value

 Is Zealand Pharma undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Zealand Pharma to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Zealand Pharma.

DB:22Z Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 8 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 5.3%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:22Z
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 5.4%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.05
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.048 (1 + (1- 22%) (1.07%))
1.038
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.04
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (1.038 * 5.44%)
5.26%

Discounted Cash Flow Calculation for DB:22Z using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Zealand Pharma is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

DB:22Z DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (DKK, Millions) Source Present Value
Discounted (@ 5.26%)
2020 -479.50 Analyst x2 -455.55
2021 -577.50 Analyst x4 -521.25
2022 -471.00 Analyst x3 -403.89
2023 -96.50 Analyst x2 -78.62
2024 441.50 Analyst x2 341.72
2025 708.37 Est @ 60.45% 520.90
2026 1,007.26 Est @ 42.19% 703.69
2027 1,303.59 Est @ 29.42% 865.23
2028 1,570.52 Est @ 20.48% 990.34
2029 1,793.80 Est @ 14.22% 1,074.64
Present value of next 10 years cash flows DKK3,037.00
DB:22Z DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= DKK1,793.80 × (1 + -0.39%) ÷ (5.26% – -0.39%)
DKK31,641.28
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= DKK31,641.28 ÷ (1 + 5.26%)10
DKK18,955.78
DB:22Z Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= DKK3,037.00 + DKK18,955.78
DKK21,992.78
Equity Value per Share
(DKK)
= Total value / Shares Outstanding
= DKK21,992.78 / 36.82
DKK597.24
DB:22Z Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:22Z represents 0.13577x of CPSE:ZEAL
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.13577x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (DKK) x Listing Adjustment Factor
= DKK 597.24 x 0.13577
€81.09
Value per share (EUR) From above. €81.09
Current discount Discount to share price of €29.68
= -1 x (€29.68 - €81.09) / €81.09
63.4%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Zealand Pharma is available for.
Intrinsic value
>50%
Share price is €29.68 vs Future cash flow value of €81.09
Current Discount Checks
For Zealand Pharma to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Zealand Pharma's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Zealand Pharma's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Zealand Pharma's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Zealand Pharma's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:22Z PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in DKK DKK-16.91
CPSE:ZEAL Share Price ** CPSE (2020-04-08) in DKK DKK218.6
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 43.07x
Germany Market PE Ratio Median Figure of 402 Publicly-Listed Companies 17.07x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Zealand Pharma.

DB:22Z PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CPSE:ZEAL Share Price ÷ EPS (both in DKK)

= 218.6 ÷ -16.91

-12.93x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Zealand Pharma is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Zealand Pharma is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Zealand Pharma's expected growth come at a high price?
Raw Data
DB:22Z PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -12.93x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts
42.4%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.71x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.24x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Zealand Pharma, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Zealand Pharma's assets?
Raw Data
DB:22Z PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in DKK DKK34.53
CPSE:ZEAL Share Price * CPSE (2020-04-08) in DKK DKK218.6
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.37x
Germany Market PB Ratio Median Figure of 573 Publicly-Listed Companies 1.47x
DB:22Z PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CPSE:ZEAL Share Price ÷ Book Value per Share (both in DKK)

= 218.6 ÷ 34.53

6.33x

* Primary Listing of Zealand Pharma.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Zealand Pharma is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Zealand Pharma's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Zealand Pharma has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Zealand Pharma expected to perform in the next 1 to 3 years based on estimates from 8 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
42.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Zealand Pharma expected to grow at an attractive rate?
  • Zealand Pharma's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • Zealand Pharma's earnings growth is expected to exceed the Germany market average.
  • Zealand Pharma's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:22Z Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:22Z Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts 42.4%
DB:22Z Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 8 Analysts 49.5%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 38.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:22Z Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
All numbers in DKK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:22Z Future Estimates Data
Date (Data in DKK Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 1,928 -185 577 6
2023-12-31 1,166 -431 -4 6
2022-12-31 528 -485 -427 7
2021-12-31 203 -591 -633 8
2020-12-31 236 -508 -534 8
2020-04-09
DB:22Z Past Financials Data
Date (Data in DKK Millions) Revenue Cash Flow Net Income *
2019-12-31 41 -409 -572
2019-09-30 43 -390 -508
2019-06-30 33 -345 524
2019-03-31 28 -319 551
2018-12-31 38 -461 581
2018-09-30 35 -417 601
2018-06-30 74 -310 -361
2018-03-31 68 -320 -346
2017-12-31 136 -279 -274
2017-09-30 306 -64 -112
2017-06-30 307 -113 -100
2017-03-31 306 -52 -102

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Zealand Pharma's earnings are expected to grow significantly at over 20% yearly.
  • Zealand Pharma's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:22Z Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below

All data from Zealand Pharma Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:22Z Future Estimates Data
Date (Data in DKK Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 7.77 21.64 -6.10 2.00
2023-12-31 -5.64 1.43 -12.70 2.00
2022-12-31 -14.18 -9.12 -19.67 4.00
2021-12-31 -17.95 -11.78 -22.68 8.00
2020-12-31 -15.22 -14.20 -17.32 4.00
2020-04-09
DB:22Z Past Financials Data
Date (Data in DKK Millions) EPS *
2019-12-31 -16.91
2019-09-30 -15.71
2019-06-30 16.93
2019-03-31 17.93
2018-12-31 18.94
2018-09-30 19.37
2018-06-30 -11.89
2018-03-31 -11.89
2017-12-31 -9.85
2017-09-30 -4.26
2017-06-30 -3.96
2017-03-31 -4.14

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Zealand Pharma will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Zealand Pharma's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Zealand Pharma has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Zealand Pharma performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Zealand Pharma's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Zealand Pharma does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Zealand Pharma's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Zealand Pharma's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Zealand Pharma's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Zealand Pharma Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:22Z Past Revenue, Cash Flow and Net Income Data
Date (Data in DKK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 41.33 -571.54 67.88 561.42
2019-09-30 42.96 -508.24 74.83 515.65
2019-06-30 33.04 524.30 69.10 479.47
2019-03-31 28.26 551.13 56.69 464.09
2018-12-31 37.98 581.28 43.54 438.22
2018-09-30 35.38 601.00 49.20 393.96
2018-06-30 74.47 -361.44 46.85 375.37
2018-03-31 68.43 -346.29 51.69 346.79
2017-12-31 136.32 -274.41 47.34 323.95
2017-09-30 306.31 -111.86 57.86 292.88
2017-06-30 306.80 -99.64 55.13 274.25
2017-03-31 305.66 -102.43 60.97 259.10
2016-12-31 230.86 -157.30 58.60 262.06
2016-09-30 221.38 -137.86 51.26 243.16
2016-06-30 189.02 -157.94 55.03 237.42
2016-03-31 188.38 -138.53 47.86 223.60
2015-12-31 187.68 -113.96 47.82 211.74
2015-09-30 26.87 -245.71 47.55 217.05
2015-06-30 77.82 -177.87 44.32 212.27
2015-03-31 74.82 -147.07 39.33 194.90
2014-12-31 153.77 -64.99 39.83 180.04
2014-09-30 150.65 -46.80 31.24 160.24
2014-06-30 94.79 -98.25 32.97 150.74
2014-03-31 91.57 -97.50 35.09 147.14
2013-12-31 6.57 -183.68 34.16 164.47
2013-09-30 3.40 -191.37 33.93 177.37
2013-06-30 38.45 -157.36 32.91 186.25

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Zealand Pharma has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Zealand Pharma has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Zealand Pharma improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Zealand Pharma's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Zealand Pharma has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Zealand Pharma's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Zealand Pharma's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Zealand Pharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Zealand Pharma's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Zealand Pharma's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 1.0041971637874E+17x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Zealand Pharma Company Filings, last reported 3 months ago.

DB:22Z Past Debt and Equity Data
Date (Data in DKK Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 1,242.67 0.00 1,380.51
2019-09-30 1,409.19 0.00 1,543.24
2019-06-30 966.78 0.00 1,142.09
2019-03-31 1,084.29 0.00 1,263.31
2018-12-31 1,116.28 0.00 1,159.25
2018-09-30 1,240.77 0.00 1,478.61
2018-06-30 316.24 143.44 461.34
2018-03-31 437.06 134.15 561.10
2017-12-31 514.67 135.73 663.83
2017-09-30 638.98 141.90 774.65
2017-06-30 181.53 146.05 302.11
2017-03-31 252.69 161.49 410.27
2016-12-31 278.19 332.24 323.33
2016-09-30 217.63 312.15 224.64
2016-06-30 107.52 311.22 289.36
2016-03-31 178.64 301.93 358.76
2015-12-31 252.23 312.95 418.80
2015-09-30 159.43 333.23 453.89
2015-06-30 163.04 301.12 468.61
2015-03-31 209.18 308.69 523.98
2014-12-31 252.83 272.17 516.85
2014-09-30 316.22 0.00 303.81
2014-06-30 299.36 0.00 297.62
2014-03-31 344.99 0.00 349.65
2013-12-31 316.14 0.00 310.56
2013-09-30 361.90 0.00 357.83
2013-06-30 396.03 0.00 403.58
  • Zealand Pharma's level of debt (0%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (108% vs 0% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Zealand Pharma has sufficient cash runway for more than 3 years based on current free cash flow.
  • Zealand Pharma has sufficient cash runway for 2.7 years if free cash flow continues to reduce at historical rates of -27% each year.
X
Financial health checks
We assess Zealand Pharma's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Zealand Pharma has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Zealand Pharma's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Zealand Pharma dividends. Estimated to be 0% next year.
If you bought €2,000 of Zealand Pharma shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Zealand Pharma's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Zealand Pharma's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:22Z Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 314 Stocks 3.6%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 4.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:22Z Future Dividends Estimate Data
Date (Data in DKK) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31 0.00 2.00
2020-12-31 0.00 2.00
2020-04-09

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Zealand Pharma has not reported any payouts.
  • Unable to verify if Zealand Pharma's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Zealand Pharma's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Zealand Pharma has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Zealand Pharma's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Zealand Pharma's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Zealand Pharma afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Zealand Pharma has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Zealand Pharma's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Emmanuel Dulac
COMPENSATION DKK15,914,300
AGE 50
TENURE AS CEO 1 years
CEO Bio

Dr. Emmanuel Dulac, PharmD, PhD, MBA, has been Chief Executive Officer at Zealand Pharma A/S since April 22, 2019 and its President since 2019. He had been Chief Commercial Officer and Senior Vice President of Alnylam Pharmaceuticals, Inc. from September 19, 2016 to June 2018 and its Chief International Strategy since August 2016. Dr. Dulac has more than 20 years of international experience in the biotech and pharmaceutical industry. He joined Alnylam Pharmaceuticals, from Shire, where he was Senior Vice President, Global Head of the Rare Disease Business Unit and General Manager of United States Operations from June 2014 to August 2016. Dr. Dulac held several leadership roles of increasing responsibility at Novartis (NYSE:NVS) from February 2006 to May 2014, including Vice President, Global Head Lung/Cystic Fibrosis. From August 2003 to February 2006, he was Business Unit Lead for Cardiovascular Medicine at Abbott (NYSE:ABT). Dr. Dulac held several roles of increasing responsibility at Sanofi (NASDAQ:SNY) from October 1994 to August 2003, including Associate Director. During his career, he successfully launched six brands, led two blockbuster drugs globally and built large sales organizations, innovative patient services and strong marketing and market access teams. He has been a Director of Proteostasis Therapeutics, Inc. since February 5, 2019. He graduated from the University of Paris XI with a Doctorate in Pharmacology (PharmD, Ph.D.) and completed an MBA from the ESSEC School in Paris.

CEO Compensation
  • Insufficient data for Emmanuel to compare compensation growth.
  • Emmanuel's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Zealand Pharma management team in years:

1
Average Tenure
47
Average Age
  • The average tenure for the Zealand Pharma management team is less than 2 years, this suggests a new team.
Management Team

Emmanuel Dulac

TITLE
CEO & President
COMPENSATION
DKK16M
AGE
50
TENURE
1 yrs

Matt Dallas

TITLE
Senior VP & CFO
COMPENSATION
DKK3M
AGE
44
TENURE
0.5 yrs

Hanne Bak

TITLE
Senior Project Director
COMPENSATION
DKK400K
AGE
66

Adam Steensberg

TITLE
Executive VP of Research & Development and Chief Medical Officer
COMPENSATION
DKK7M
AGE
45
TENURE
1 yrs

Ivan Møller

TITLE
Senior Vice President of Technical Development & Operations
AGE
47
TENURE
2.1 yrs

Rie Hansen

TITLE
Interim Chief Scientific Officer & VP of Research
TENURE
0.7 yrs

Lani Morvan

TITLE
Investor Relations & Communications Officer

Søren Keller

TITLE
Head of Legal Affairs
TENURE
6 yrs

Niels Mørk

TITLE
Head of Bioanalysis

Jens Mikkelsen

TITLE
Head of Molecular Pharmacology
Board of Directors Tenure

Average tenure and age of the Zealand Pharma board of directors in years:

8.4
Average Tenure
64
Average Age
  • The tenure for the Zealand Pharma board of directors is about average.
Board of Directors

Alf Gunnar Nicklasson

TITLE
Independent Chairman of the Board
COMPENSATION
DKK850K
AGE
64
TENURE
5 yrs

Kirsten Drejer

TITLE
Independent Vice Chairman
COMPENSATION
DKK467K
AGE
63
TENURE
1 yrs

Hanne Bak

TITLE
Senior Project Director
COMPENSATION
DKK400K
AGE
66
TENURE
4 yrs

Alain Munoz

TITLE
Co-Chair of the Clinical & Scientific Advisory Board & Director
COMPENSATION
DKK450K
AGE
70
TENURE
8.4 yrs

Leon Kruimer

TITLE
Independent Director
COMPENSATION
DKK367K
AGE
61
TENURE
1 yrs

Tyge Korsgaard

TITLE
Board Observer
AGE
62

Bernard Charbonnel

TITLE
Member of Advisory Board
TENURE
8.4 yrs

Richard Pratley

TITLE
Member of Advisory Board
TENURE
8.4 yrs

Paul Dorian

TITLE
Member of Advisory Board
TENURE
8.4 yrs

Ake Lernmark

TITLE
Member of Advisory Board
AGE
74
TENURE
8.4 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Zealand Pharma's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Zealand Pharma has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Zealand Pharma A/S, a biotechnology company, engages in the discovery and development of peptide based medicines in Denmark. It has a portfolio of medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide under the brand names of Adlyxin, Lyxumia, Soliqua 100/33, and Suliqua. Its product pipeline includes glepaglutide, a long acting GLP-2 analog, which is in Phase 3 clinical trials for the treatment of short bowel syndrome; and dasiglucagon, a stable glucagon analog for the treatment of severe hypoglycemia in diabetes and congenital hyperinsulinism, as well as for use in dual-hormone automated pump therapy for management of type 1 diabetes. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; and Beta Bionics, Inc. to initiate home-use trial of the iLet bionic pancreas with dasiglucagon for autonomous bihormonal treatment of type 1 diabetes, as well as research agreement with Orbit Discovery Ltd. and Torrey Pines Institute for Molecular Studies. The company was founded in 1997 and is headquartered in Copenhagen, Denmark.

Details
Name: Zealand Pharma A/S
22Z
Exchange: DB
Founded: 1997
DKK1,078,736,598
36,823,729
Website: http://www.zealandpharma.com
Address: Zealand Pharma A/S
Sydmarken 11,
Søborg,
Copenhagen,
Capital Region of Denmark, Denmark
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CPSE ZEAL Ordinary Shares OMX Nordic Exchange Copenhagen DK DKK 23. Nov 2010
OTCPK ZLDP.F Ordinary Shares Pink Sheets LLC US USD 23. Nov 2010
DB 22Z Ordinary Shares Deutsche Boerse AG DE EUR 23. Nov 2010
LSE 0NZU Ordinary Shares London Stock Exchange GB DKK 23. Nov 2010
BATS-CHIXE ZEALC Ordinary Shares BATS 'Chi-X Europe' GB DKK 23. Nov 2010
NasdaqGS ZEAL ADR EACH REP 1 ORD SHS SPON Nasdaq Global Select US USD 09. Aug 2017
DB 22ZA ADR EACH REP 1 ORD SHS SPON Deutsche Boerse AG DE EUR 09. Aug 2017
Number of employees
Current staff
Staff numbers
179
Zealand Pharma employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/09 02:20
End of day share price update: 2020/04/08 00:00
Last estimates confirmation: 2020/04/01
Last earnings filing: 2020/03/12
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.